DataM Intelligence

Market Overview

Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia, and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. The signs and symptoms of cachexia are considered the prognostic parameters in cancer patients. The pathogenicity of this syndrome is multifactorial due to a complex interaction of tumor and host factors. Cancer cachexia drugs are used to treat or alleviate the condition.

Download free sample @ https://www.datamintelligence.com/download-sample/cancer-cachexia-market

Market Dynamics

The global cancer cachexia market growth is driven by the expansion in the prevalence of serious health conditions, for instance, cancer, and the rising number of cachexia among these patients. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia.

The strong R&D and product pipeline will drive the market growth    

Most of the major players are focused on R&D activities to develop highly effective novel drugs in the treatment of cancer cachexia. This factor resulted in an increased pipeline of therapeutics waiting for approval and commercial launch post-approval. For instance, clinicaltrials.gov reported that, as of February 7, 2022, a total of 141 studies were conducted or were being conducted to develop drugs that treat cancer cachexia.

The current treatment options for cachexia among cancer patients are limited to drugs namely, progestogens, corticosteroids, and others. These drugs have proved their efficiency in the treatment of cancer-induced cachexia, although there is a clinical gap in the treatment outcomes. At present, there is no drug candidate is specifically approved for the treatment of this condition. This augments the gap in treatment options, which the market players are aiming to fulfill through R&D and the introduction of new drugs in the global market. For instance, PF-06946860, which is being sponsored by Pfizer Inc., is currently in Phase 1 of clinical trials. The purpose of this trial is to study the efficacy of PF-06946860 in the treatment of non-small cell lung cancer (NSCLC) patients with cachexia. The success of the clinical trials of new candidates, regulatory approvals, and introductions of these drugs are anticipated to further boost the demand and adoption among the healthcare providers of cancer cachexia therapeutics.

Market Segmentation

By Therapeutics

• Corticosteroids
• Cannabinoids (Dronabinol)
• Anabolic Steriods

By Mechanism

• Appetite Stimulators
• Weight Loss Stabilizers
• Others  

By Distribution Channel 

• Hospital Stores
• Retail Pharmacy Stores
• Online Pharmacy

View full report @ https://www.datamintelligence.com/research-report/cancer-cachexia-market

Competitive Landscape

The cancer cachexia market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KgaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cancer Cachexia Market globally. For instance, in February 2021, Artelo Biosciences Inc. collaborated with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia.

Trending Topic’s

Insomnia Treatment Market

Myelodysplastic Syndrome (MDS) Treatment Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/cancer-cachexia-market